Conclusions The therapeutic scope of GLP-1R agonists is expanding beyond traditional metabolic targets, highlighting its potential for headache and pain disorders
We employ 4,900 physicians, and we are leaders in clinical care, groundbreaking research, and treatment breakthroughs
The body composition benefits of resistance training during GLP-1 therapy are irreplaceable
The EMPA-REG OUTCOME trial (SGLT2i) showed a rapid onset of cardiovascular benefit, with event curve separation as early as three months, likely driven by hemodynamic effects such as volume reduction and improved heart failure outcomes [55]
Data were sourced from TriNetX, a network of 70 US health care organizations, using diagnostic codes to identify eligible patients while excluding those with hepatocellular carcinoma or cholangiocarcinoma